The investment will expand RNA T&T's operations and allow partners of both companies to leverage combined expertise in RNA-LNP therapeutics.

Ancient DNA has been pulled from a permafrost-preserved woolly mammoth found in Siberia, and scientists are thrilled. They ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

A new research paper featured as the cover of Volume 17, Issue 12 of Aging-US was published on December 22, 2025, titled “A ...

Our results demonstrate that differential connectivity analysis reveals significant transcriptional alterations that are not ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Alnylam, Ionis, and Sarepta lead the RNA ...

RNA Drugs: presented yesterday in Naples, at the research area of Naples of the CNR, in via Pietro Castellino, the results of ...

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.

Descartes-08, a BCMA-directed rCAR T, improved MG severity in 72% of patients at 12 months, with significant improvements seen as early as 3 months. Ex vivo T-cell proliferation in Descartes-08 allows ...